87 research outputs found

    Entwicklung und Einflussgrößen der gesunden Lebenserwartung

    Get PDF
    Die demographische Alterung stellt eine bedeutende Herausforderung der deutschen Gesundheitspolitik dar. Die zentrale Frage lautet heute nicht mehr, ob die Bevölkerung immer älter wird, sondern ob hinzugewonnene Lebensjahre bei guter Gesundheit verbracht werden können. In diesem Beitrag wird ein Überblick über den Forschungsstand zur Entwicklung und zu Einflussgrößen der gesunden Lebenserwartung gegeben. Die für Deutschland vorliegenden Ergebnisse sprechen insgesamt dafür, dass die Bevölkerung immer länger lebt und auch länger gesund bleibt. Diese positive Entwicklung könnte auch den prognostizierten Ausgabenanstieg im Gesundheitssystem dämpfen. Allerdings profitieren nicht alle Bevölkerungsgruppen gleichermaßen vom Anstieg der gesunden Lebenszeit, da große soziale Ungleichheiten in den Chancen auf ein langes und gesundes Leben bestehen. -- Demographic ageing is a major challenge of health policy in Germany. The main question is no longer if the population of Germany is getting older, but whether gained life years will be in a healthy condition or not. This paper gives an overview on current research and evidence regarding trends and determinants of the healthy life expectancy. Recent Evidence for Germany seems to suggest that the population of Germany is going to live even longer and in a better health state. These positive trends may attenuate the expected increase of health costs during the process of demographic ageing. On the other hand there is evidence that not all parts of the population benefit from rising life expectancy. There are lasting social inequalities regarding the chances of a long and healthy life.Gesunde Lebenserwartung,Bevölkerungsentwicklung,Soziale Ungleichheit,healthy life expectancy,demographic change,social inequality

    Entwicklung und Einflussgrößen der gesunden Lebenserwartung

    Full text link
    "Die demographische Alterung stellt eine bedeutende Herausforderung der deutschen Gesundheitspolitik dar. Die zentrale Frage lautet heute nicht mehr, ob die Bevölkerung immer älter wird, sondern ob hinzugewonnene Lebensjahre bei guter Gesundheit verbracht werden können. In diesem Beitrag wird ein Überblick über den Forschungsstand zur Entwicklung und zu Einflussgrößen der gesunden Lebenserwartung gegeben. Die für Deutschland vorliegenden Ergebnisse sprechen insgesamt dafür, dass die Bevölkerung immer länger lebt und auch länger gesund bleibt. Diese positive Entwicklung könnte auch den prognostizierten Ausgabenanstieg im Gesundheitssystem dämpfen. Allerdings profitieren nicht alle Bevölkerungsgruppen gleichermaßen vom Anstieg der gesunden Lebenszeit, da große soziale Ungleichheiten in den Chancen auf ein langes und gesundes Leben bestehen." (Autorenreferat)"Demographic ageing is a major challenge of health policy in Germany. The main question is no longer if the population of Germany is getting older, but whether gained life years will be in a healthy condition or not. This paper gives an overview on current research and evidence regarding trends and determinants of the healthy life expectancy. Recent Evidence for Germany seems to suggest that the population of Germany is going to live even longer and in a better health state. These positive trends may attenuate the expected increase of health costs during the process of demographic ageing. On the other hand there is evidence that not all parts of the population benefit from rising life expectancy. There are lasting social inequalities regarding the chances of a long and healthy life." (author's abstract

    Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

    Get PDF
    Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

    Search for single production of vector-like quarks decaying into Wb in pp collisions at s=8\sqrt{s} = 8 TeV with the ATLAS detector

    Get PDF

    Measurement of the charge asymmetry in top-quark pair production in the lepton-plus-jets final state in pp collision data at s=8TeV\sqrt{s}=8\,\mathrm TeV{} with the ATLAS detector

    Get PDF

    ATLAS Run 1 searches for direct pair production of third-generation squarks at the Large Hadron Collider

    Get PDF

    Measurement of the W boson polarisation in ttˉt\bar{t} events from pp collisions at s\sqrt{s} = 8 TeV in the lepton + jets channel with ATLAS

    Get PDF

    Measurements of top-quark pair differential cross-sections in the eμe\mu channel in pppp collisions at s=13\sqrt{s} = 13 TeV using the ATLAS detector

    Get PDF
    corecore